预测大肠癌化疗疗效的分子或基因指标

用于治疗大肠癌的药物主要有氟尿嘧啶、卡培他宾、依立替康、奥沙利铂、昔妥单抗、贝伐单抗,使大肠癌的化疗有效率明显提高,病人中位生存时间明显延长。但大肠癌化疗中原发和获得性耐药现象很普遍。一些分子或基因指标有可能预测大肠患者能否从辅助化疗或姑息化疗中获益。这篇综述主要回顾预测大肠癌化疗药物疗效的分子和基因指标,分析其联系,从而指导临床按个体化原则用药。

Molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer

Several antineoplastic agents(5-FU,capecitabine,irinotecan,oxaliplatin,cetuximab,bevacizumab)are licensed for use in patients with colorectal cancer,which better the response rate of chemotherapy and median survival.But,primary and acquired treatment resistance is common in colorectal cancer.Some molecular and genetic markers might predict whether colorectal cancer patients are likely to benefit from adjuvant or salvage therapy.The article will review several molecular or genetic markers,which can predict the chemotherapy outcome of most commonly used agents in colorectal cancer,through those marker lead tailor individual treatment.